221 related articles for article (PubMed ID: 21422117)
1. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.
Mohty B; Bel M; Vukicevic M; Nagy M; Levrat E; Meier S; Grillet S; Combescure C; Kaiser L; Chalandon Y; Passweg J; Siegrist CA; Roosnek E; ;
Haematologica; 2011 Jun; 96(6):896-904. PubMed ID: 21422117
[TBL] [Abstract][Full Text] [Related]
2. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.
Dhédin N; Krivine A; Le Corre N; Mallet A; Lioure B; Bay JO; Rubio MT; Agape P; Thiébaut A; Le Goff J; Autran B; Ribaud P
Vaccine; 2014 Jan; 32(5):585-91. PubMed ID: 24333120
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation.
Gueller S; Allwinn R; Mousset S; Martin H; Wieters I; Herrmann E; Serve H; Bickel M; Bug G
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1546-50. PubMed ID: 21324375
[TBL] [Abstract][Full Text] [Related]
4. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine.
Siegrist CA; Ambrosioni J; Bel M; Combescure C; Hadaya K; Martin PY; Soccal PM; Berney T; Noble S; Meier S; Posfay-Barbe K; Grillet S; Kaiser L; van Delden C;
Antivir Ther; 2012; 17(5):893-903. PubMed ID: 22544169
[TBL] [Abstract][Full Text] [Related]
5. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
Engelhard D; Zakay-Rones Z; Shapira MY; Resnick I; Averbuch D; Grisariu S; Dray L; Djian E; Strauss-Liviatan N; Grotto I; Wolf DG; Or R
Vaccine; 2011 Feb; 29(9):1777-82. PubMed ID: 21216315
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.
Hottinger AF; George AC; Bel M; Favet L; Combescure C; Meier S; Grillet S; Posfay-Barbe K; Kaiser L; Siegrist CA; Dietrich PY;
Oncologist; 2012; 17(3):436-45. PubMed ID: 22357731
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
[TBL] [Abstract][Full Text] [Related]
8. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.
Fairhead T; Hendren E; Tinckam K; Rose C; Sherlock CH; Shi L; Crowcroft NS; Gubbay JB; Landsberg D; Knoll G; Gill J; Kumar D
Transpl Infect Dis; 2012 Dec; 14(6):575-83. PubMed ID: 22999005
[TBL] [Abstract][Full Text] [Related]
9. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
11. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.
Manuel O; Pascual M; Hoschler K; Giulieri S; Alves D; Ellefsen K; Bart PA; Venetz JP; Calandra T; Cavassini M
Clin Infect Dis; 2011 Jan; 52(2):248-56. PubMed ID: 21288852
[TBL] [Abstract][Full Text] [Related]
12. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
de Lavallade H; Garland P; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; Szydlo R; Kanfer E; Macdonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K
Haematologica; 2011 Feb; 96(2):307-14. PubMed ID: 20971824
[TBL] [Abstract][Full Text] [Related]
13. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.
Issa NC; Marty FM; Gagne LS; Koo S; Verrill KA; Alyea EP; Cutler CS; Koreth J; Armand P; Ho VT; Antin JH; Soiffer RJ; Baden LR
Biol Blood Marrow Transplant; 2011 Mar; 17(3):434-8. PubMed ID: 20950701
[TBL] [Abstract][Full Text] [Related]
14. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.
Roman F; Clément F; Dewé W; Walravens K; Maes C; Willekens J; De Boever F; Hanon E; Leroux-Roels G
Clin Vaccine Immunol; 2011 May; 18(5):835-43. PubMed ID: 21450978
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
[TBL] [Abstract][Full Text] [Related]
16. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
17. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.
Natori Y; Humar A; Lipton J; Kim DD; Ashton P; Hoschler K; Kumar D
Bone Marrow Transplant; 2017 Jul; 52(7):1016-1021. PubMed ID: 28263288
[TBL] [Abstract][Full Text] [Related]
18. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.
Ferguson M; Risi G; Davis M; Sheldon E; Baron M; Li P; Madariaga M; Fries L; Godeaux O; Vaughn D
J Infect Dis; 2012 Mar; 205(5):733-44. PubMed ID: 22315336
[TBL] [Abstract][Full Text] [Related]
19. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
